利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.034 秒)

    THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE
    33.
    发明申请
    THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE 审中-公开
    根据免疫应答的自适应，消除和/或法规组成部分治疗癌症

    公开(公告)号：US20100150999A1

    公开(公告)日：2010-06-17

    申请号：US12439379

    申请日：2007-07-16

    申请人： Claude Leclerc ,  Pedro Berraondo Lopez

    发明人： Claude Leclerc ,  Pedro Berraondo Lopez

    IPC分类号： A61K9/127 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/555 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/33 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/88 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12Y406/01001

    摘要： The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patient.

    摘要翻译： 本发明涉及一种适合用于癌症治疗的试剂盒，其中所述试剂盒包括：（i）包含一个或几个携带一个或几个肿瘤相关抗原表位的多肽的重组蛋白，所述多肽 插入腺苷酸环化酶（CyaA）蛋白或其片段的相同或不同的允许位点，其中所述CyaA片段保留所述腺苷酸环化酶蛋白质的特性以靶向抗原呈递细胞或其重要蛋白质的混合物，其中至少 所述表位之一或肿瘤相关抗原或CyaA蛋白的插入位点或所述CyaA蛋白的片段在混合物中的各种重组蛋白之间是不同的; 并且所述试剂盒的部分还包含至少一种以下化合物; （ii）任选的适于调节患者的调节免疫应答的药剂; （iii）适合于激活患者中先天免疫应答的辅助成分。

    Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
    35.
    发明授权
    Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof 有权
    包含其的多抗原糖肽糖蛋白疫苗及其应用

    公开(公告)号：US06676946B2

    公开(公告)日：2004-01-13

    申请号：US09405986

    申请日：1999-09-27

    申请人： Sylvie Bay ,  Daniele Cantacuzene ,  Claude Leclerc ,  Richard Lo-Man ,  Sophie Vicher-Guerre

    发明人： Sylvie Bay ,  Daniele Cantacuzene ,  Claude Leclerc ,  Richard Lo-Man ,  Sophie Vicher-Guerre

    IPC分类号： A61K39385

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K47/645 ,  A61K2039/55505 ,  A61K2039/645 ,  C07K9/001 ,  C07K14/001 ,  C07K14/22 ,  C07K14/285 ,  C07K14/31 ,  C07K14/315 ,  Y02A50/466

    摘要： A carbohydrate peptide conjugate containing: (i) a carrier containing a dendrimeric poly-lysine enabling multiple epitopes to be covalently attached thereto, (ii) at least one peptide containing one T epitope or several identical or different T-epitopes, (iii) at least one carbohydrate moiety which is tumor antigen, or a derivative thereof, containing a B epitope, provided it is not a sialoside, or several identical or different epitopes, wherein said conjugate containing at least 3-lysines and up to 15 lysine covalently linked to one another, and wherein: (a) to the NH2 and of at least two lysine residues is bound at least one carbohydrate residue being not a sialoside, optionally substituted and containing an epitope and wherein the peptide containing one T epitope is covalently bound to the end of said carbohydrate which induces immune responses.

    摘要翻译： 一种碳水化合物肽缀合物，其含有：（i）含有多个表位与其共价连接的树状多聚赖氨酸的载体，（ii）至少一种含有一个T表位或几个相同或不同T表位的肽，（iii） 至少一个是含有B表位的肿瘤抗原或其衍生物的碳水化合物部分，只要它不是唾液酸苷或几个相同或不同的表位，其中所述含至少3个赖氨酸和至多15个赖氨酸的缀合物共价连接到 并且其中：（a）到NH 2和至少两个赖氨酸残基的至少一个碳水化合物残基不是唾液酸苷，任选地被取代并含有表位，并且其中含有一个T表位的肽共价结合到 所述碳水化合物的末端诱导免疫应答。

    Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
    37.
    发明授权
    Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell 有权
    突变型CyaA多肽和多肽衍生物，适于将免疫原性分子递送至细胞中

    公开(公告)号：US09222143B2

    公开(公告)日：2015-12-29

    申请号：US13257569

    申请日：2010-03-23

    申请人： Peter Sebo ,  Adriana Osickova ,  Jiri Masin ,  Catherine Fayolle ,  Jan Krusek ,  Marek Basler ,  Claude Leclerc ,  Radim Osicka

    发明人： Peter Sebo ,  Adriana Osickova ,  Jiri Masin ,  Catherine Fayolle ,  Jan Krusek ,  Marek Basler ,  Claude Leclerc ,  Radim Osicka

    IPC分类号： C12N9/88

    CPC分类号： C12N9/88 ,  C12Y406/01001

    摘要： A polypeptide comprises a mutated Bordetella pertussis CyaA (SEQ ID NO:1), Bordetella parapertussis CyaA (SEQ ID NO:7), Bordetella hinzii CyaA (SEQ ID NO:8), or Bordetella bronchiseptica CyaA (SEQ ID NO:9), or a fragment thereof lacking all or part of the N-terminal catalytic domain of the CyaA, or a polypeptide having at least 95% sequence identity with SEQ ID NOS: 1, 7, 8, or 9. The glutamic acid residue at position 570 of SEQ ID NO: 1, 7, 8 or at position 569 of SEQ ID NO:9 has been substituted by a conservative amino acid residue. The lysine residue at position 860 of SEQ ID NO: 1, 7, 8 or at position 859 of SEQ ID NO:9 has been substituted by a conservative amino acid residue. The polypeptide retains the binding activity of native CyaA to CD11b expressing cell, and has a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.

    摘要翻译： 多肽包括突变型百日咳杆菌CyaA（SEQ ID NO：1），百日咳杆菌CyaA（SEQ ID NO：7），Bordetella hinzii CyaA（SEQ ID NO：8）或支气管炎博德特氏菌CyaA（SEQ ID NO：9）， 或其缺少CyaA的全部或部分N末端催化结构域的片段，或与SEQ ID NO：1,7,8或9具有至少95％序列同一性的多肽。570位的谷氨酸残基 的SEQ ID NO：1,7,8或SEQ ID NO：9的位置569已被保守的氨基酸残基取代。 SEQ ID NO：1,7,8或SEQ ID NO：9的859位的860位的赖氨酸残基被保守的氨基酸残基取代。 多肽保留天然CyaA与表达CD11b的细胞的结合活性，并且与天然CyaA毒素相比具有减少或抑制的成孔活性。

    Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
    39.
    发明授权
    Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response 有权
    基于针对免疫应答的适应性，先天和/或调节组分的癌症治疗

    公开(公告)号：US09095537B2

    公开(公告)日：2015-08-04

    申请号：US11778267

    申请日：2007-07-16

    申请人： Claude Leclerc ,  Pedro Berraondo Lopez

    发明人： Claude Leclerc ,  Pedro Berraondo Lopez

    IPC分类号： A61K39/10 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  C12N9/88

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/555 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/33 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/88 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12Y406/01001

    摘要： The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises:(i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patient.

    摘要翻译： 本发明涉及一种适合用于癌症治疗的试剂盒，其中所述试剂盒包括：（i）包含一个或几个携带一个或几个肿瘤相关抗原表位的多肽的重组蛋白，所述多肽 插入腺苷酸环化酶（CyaA）蛋白或其片段的相同或不同的允许位点，其中所述CyaA片段保留所述腺苷酸环化酶蛋白质的特性以靶向抗原呈递细胞或其重要蛋白质的混合物，其中至少 所述表位之一或肿瘤相关抗原或CyaA蛋白的插入位点或所述CyaA蛋白的片段在混合物中的各种重组蛋白之间是不同的; 并且所述试剂盒的部分还包含至少一种以下化合物; （ii）任选的适于调节患者的调节免疫应答的药剂; （iii）适合于激活患者中先天免疫应答的辅助成分。